Summary of precautions when using Cassimerson

Casimersen is an innovative drug for Duchenne muscular dystrophy (DMD). It changes the splicing pattern of mRNA to promote the production of functional dystrophin, thereby effectively alleviating the symptoms of muscle degeneration in DMD patients. Clinical trials have confirmed that it can significantly increase dystrophin levels in patients, providing a new way to treat DMD.

There are a few things that are particularly important to note when using Cassimerson. First, a comprehensive baseline assessment should be performed before medication, including measurement of serum cystatinC, urine dipstick, and urine protein/creatinine ratio (UPCR), and measurement of glomerular filtration rate should be considered to ensure that the patient's renal function can tolerate drug treatment. Because Kasimerson may be nephrotoxic, renal function needs to be monitored closely during treatment and urine samples must be obtained regularly for testing.

The drug is supplied as a concentrated solution that needs to be diluted through a 0.2 micron filter and infused intravenously for 35 to 60 minutes before administration. The recommended dose is 30 mg per kilogram of body weight once a week. During the dilution and infusion process, aseptic technical operating specifications should be strictly followed to ensure that the drugs are not contaminated. At the same time, injectable drugs should be visually inspected to confirm the absence of particulate matter and discoloration before administration. If a patient misses a dose of Casimerson, it should be taken as soon as possible after the scheduled dose to maintain continuity and effectiveness of treatment.

Adverse reactions may occur when using Casimerson, such asupper respiratory tract infection, cough, fever, headache, joint pain and oropharyngeal pain, etc. The incidence of these adverse reactions is relatively high in clinical trials. In addition, because Casimerson is a drug administered by intravenous infusion, infusion-related side effects, such as phlebitis, may occur during use.

It is recommended that patients pay close attention to their own reactions during the use of Casimerson's. If any symptoms of discomfort occur, they should seek medical treatment in time and inform the doctor. In short, the use of Casimerson must strictly follow medical instructions to ensure safe and effective medication.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213026s005lbl.pdf